



Substitute for form 1449A/PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Page 2 of 3	Applicant Number	
	Filing Date	
	First Named Inventor	John F. Gerster
	Art Unit	1625
	Examiner Name	Morris, Patricia L.
	Attorney Case Number	52690US021


U.S. Patent Documents					
Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
<i>[Signature]</i>	A29	US- 6,376,669	04-23-2002	Rice et al.	
	A30	US- 2002/0055517 A1	05-09-02	Smith	
	A31	US- 2002/0058674 A1	05-16-02	Hedenstrom et al.	
<i>[Signature]</i>	A32	US- 6,451,810	09-17-02	Coleman et al.	

Foreign Patent Documents							
Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (if known)				
<i>[Signature]</i>	B1	PCT	WO 00/47719	08-17-2000			
	B2	PCT	WO 00/76518	12-21-2000			
	B3	PCT	WO 01/74343	10-11-2001			
	B4	PCT	WO 02/36592	05-10-2002			X
	B5	PCT	WO 02/46188	06-13-2002			
	B6	PCT	WO 02/46189	06-13-2002			
	B7	PCT	WO 02/46190	06-13-2002			
	B8	PCT	WO 02/46191	06-13-2002			
	B9	PCT	WO 02/46192	06-13-2002			
	B10	PCT	WO 02/46193	06-13-2002			
	B11	PCT	WO 02/46194	06-13-2002			
	B12	PCT	WO 02/46749	06-13-2002			
	B13	PCT	WO 02/102377	12-27-2002			
	B14	JP	9-208584	08-12-1997			
	B15	JP	9-255926	03-26-1999			X
	B16	JP	11-222432	08-17-1999			X
	B17	JP	2000-247884 (abs)	09-12-2000			X
	B18	EP	0 394 026	10-24-1990			
<i>[Signature]</i>	B19	EP	1 104 764	06-06-2001			

*Examiner: <i>[Signature]</i>	Date Considered: 1-16-04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitut for form 1449A/PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Page 3 of 3	Applicati n Number	
	Filing Date	
	First Named Invent r	John F. Gerster
	Art Unit	1625
	Examiner Name	Morris, Patricia L.
	Attorney Case Number	52690US021

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	Wozniak, et al, "The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate ^{1,2} . A New and Convenient Amination Method.", <u>Journal of the Royal Netherlands Chemical Society</u> , 102, pp 511-513, December 12, 1983.
	C2	Brennan, et al, "Automated Bioassay of Interferons in Micro-test Plates", <u>Biotechniques</u> , June/July, 78, 1983.
	C3	Testerman, et al., "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", <u>Journal of Leukocyte Biology</u> , Volume 58, pp. 365-372, September 1995.
	C4	Bachman, et al, "Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline", <u>J. Org. Chem.</u> , 15, pp 1278-1284 (1950).
	C5	Jain, et al, "Chemical and Pharmacological Investigations of Some ω -Substituted Alkylamino-3-aminopyridines", <u>J. Med. Chem.</u> , 11, pp 87-92 (1968).
	C6	Baranov, et al., <u>Chem. Abs.</u> 85, 94371, (1976).
	C7	Berényi, et al, "Ring Transformation of Condensed Dihydro-as-triazines", <u>J. Heterocyclic Chem.</u> , 18, pp 1537-1540 (1981).
	C8	Chollet, et al, "Development of a Topically Active Imiquimod Formulation", <u>Pharmaceutical Development and Technology</u> , 4(1), pp 35-43 (1999)

*Examiner: 	Date Considered: 1-19-04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	